vTv Therapeutics Operating Expenses Growth & History (VTVT)
vTv Therapeutics's operating expenses was $32.8M for fiscal 2025.
View full vTv Therapeutics company overviewvTv Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $32.8M | $7.6M | +30.21% |
| 2024 | 2024-12-31 | $25.2M | −$305,000 | −1.20% |
| 2023 | 2023-12-31 | $25.5M | $944,000 | +3.84% |
| 2022 | 2022-12-31 | $24.6M | −$1.1M | −4.32% |
| 2021 | 2021-12-31 | $25.7M | $7.4M | +40.52% |
| 2020 | 2020-12-31 | $18.3M | −$5.4M | −22.78% |
| 2019 | 2019-12-31 | $23.7M | −$8.6M | −26.67% |
| 2018 | 2018-12-31 | $32.3M | −$18.7M | −36.72% |
| 2017 | 2017-12-31 | $51.0M | −$4.7M | −8.41% |
| 2016 | 2016-12-31 | $55.7M | $17.0M | +43.95% |
| 2015 | 2015-12-31 | $38.7M | $8.2M | +26.98% |
| 2014 | 2014-12-31 | $30.4M | −$6.4M | −17.29% |
| 2013 | 2013-12-31 | $36.8M | — | — |
vTv Therapeutics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.9M | $6.2M | +80.42% |
| Q1 2026 | 2026-03-31 | $13.6M | $7.1M | +108.77% |
| Q4 2025 | 2025-12-31 | $7.9M | $3.0M | +60.62% |
| Q3 2025 | 2025-09-30 | $10.7M | $4.2M | +64.45% |
| Q2 2025 | 2025-06-30 | $7.7M | $566,000 | +7.91% |
| Q1 2025 | 2025-03-31 | $6.5M | −$124,000 | −1.87% |
| Q4 2024 | 2024-12-31 | $4.9M | $202,000 | +4.29% |
| Q3 2024 | 2024-09-30 | $6.5M | $1.1M | +21.20% |
| Q2 2024 | 2024-06-30 | $7.2M | −$845,000 | −10.56% |
| Q1 2024 | 2024-03-31 | $6.6M | −$800,000 | −10.77% |
| Q4 2023 | 2023-12-31 | $4.7M | −$1.6M | −25.90% |
| Q3 2023 | 2023-09-30 | $5.4M | −$321,000 | −5.64% |
| Q2 2023 | 2023-06-30 | $8.0M | $4.0M | +98.22% |
| Q1 2023 | 2023-03-31 | $7.4M | −$1.1M | −12.43% |
| Q4 2022 | 2022-12-31 | $6.4M | −$4.8M | −42.87% |
| Q3 2022 | 2022-09-30 | $5.7M | $1.1M | +23.59% |
| Q2 2022 | 2022-06-30 | $4.0M | −$643,000 | −13.74% |
| Q1 2022 | 2022-03-31 | $8.5M | $3.2M | +61.02% |
| Q4 2021 | 2021-12-31 | $11.1M | $6.5M | +143.34% |
| Q3 2021 | 2021-09-30 | $4.6M | $1.8M | +62.13% |
| Q2 2021 | 2021-06-30 | $4.7M | $475,000 | +11.30% |
| Q1 2021 | 2021-03-31 | $5.3M | −$1.4M | −20.84% |
| Q4 2020 | 2020-12-31 | $4.6M | −$1.8M | −28.55% |
| Q3 2020 | 2020-09-30 | $2.8M | −$2.6M | −47.75% |
| Q2 2020 | 2020-06-30 | $4.2M | −$2.4M | −36.50% |
| Q1 2020 | 2020-03-31 | $6.7M | $1.4M | +27.76% |
| Q4 2019 | 2019-12-31 | $6.4M | $1.5M | +31.23% |
| Q3 2019 | 2019-09-30 | $5.4M | $577,000 | +11.88% |
| Q2 2019 | 2019-06-30 | $6.6M | −$4.7M | −41.58% |
| Q1 2019 | 2019-03-31 | $5.2M | −$6.0M | −53.49% |
| Q4 2018 | 2018-12-31 | $4.9M | −$8.1M | −62.53% |
| Q3 2018 | 2018-09-30 | $4.9M | −$6.7M | −57.98% |
| Q2 2018 | 2018-06-30 | $11.3M | −$1.3M | −10.27% |
| Q1 2018 | 2018-03-31 | $11.2M | −$2.6M | −18.76% |
| Q4 2017 | 2017-12-31 | $13.0M | −$346,000 | −2.59% |
| Q3 2017 | 2017-09-30 | $11.6M | −$2.0M | −14.82% |
| Q2 2017 | 2017-06-30 | $12.6M | −$2.2M | −14.80% |
| Q1 2017 | 2017-03-31 | $13.8M | −$132,000 | −0.95% |
| Q4 2016 | 2016-12-31 | $13.4M | $2.0M | +17.97% |
| Q3 2016 | 2016-09-30 | $13.6M | $4.0M | +41.70% |
| Q2 2016 | 2016-06-30 | $14.8M | $6.8M | +85.29% |
| Q1 2016 | 2016-03-31 | $13.9M | $4.1M | +42.42% |
| Q4 2015 | 2015-12-31 | $11.3M | — | — |
| Q3 2015 | 2015-09-30 | $9.6M | $3.7M | +61.72% |
| Q2 2015 | 2015-06-30 | $8.0M | — | — |
| Q1 2015 | 2015-03-31 | $9.8M | — | — |
| Q3 2014 | 2014-09-30 | $5.9M | — | — |
vTv Therapeutics operating expenses trends
Over the last five fiscal years, vTv Therapeutics's operating expenses increased from $18.3M to $32.8M, a change of $14.5M. The latest reported quarter, Q2 2026, shows $13.9M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review vTv Therapeutics source filings ↗